Breaking News, Collaborations & Alliances

Aprecia, Cycle Partner to Develop 3D-Printed Orphan Drugs

Will use Aprecia's proprietary 3DP ZipDose Technology platform.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Aprecia Pharmaceuticals and Cycle Pharmaceuticals have signed a partnership agreement to develop and commercialize orphan drugs using three-dimensionally printed (3DP) technology. The planned products will deliver quality-of-life improvements versus existing, approved orphan drugs, and will achieve this by utilizing Aprecia’s proprietary 3DP ZipDose Technology platform. ZipDose is the only three-dimensional printing technology used in a pharmaceutical drug product approved by the U.S. Food...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters